Biogen Avonex
Executive Summary
The multiple sclerosis treatment does not infringe upon either of Berlex' "McCormick" patents relating to methods of producing interferon beta products, a Massachusetts federal court summary judgement concluded Aug. 15. Berlex, which filed the lawsuit and markets the competing MS interferon beta product Betaseron with Chiron in the U.S., has indicated that it expects to appeal the ruling pending final judgement